Analysis of US food and drug administration warning letters: False promotional claims relating to prescription and over-the-counter medications

Pharmaceutical Medicine

Volumn 22, Issue 2, 2008, Pages 119-125

  Salas, Maribel ^a,c   Martin, Michelle ^a   Pisu, Maria ^a   McCall, Erin ^a   Zuluaga, Alvaro ^b   Glasser, Stephen P ^a  

^a University of Alabama at Birmingham   (United States)

^b Department of Hematology   (Mexico)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Food and Drug Administration; Legislation; Marketing; Pharmaceutical industry

Indexed keywords

ANALGESIC AGENT; ANESTHETIC AGENT; ANTIDIABETIC AGENT; ERGOTAMINE; EXPECTORANT AGENT; GUAIFENESIN; HORMONE; PROGESTERONE;

ARTICLE; DRUG APPROVAL; DRUG EFFICACY; DRUG LABELING; DRUG MANUFACTURE; DRUG MARKETING; DRUG RESEARCH; DRUG SCREENING; FOOD AND DRUG ADMINISTRATION; HUMAN; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SMOKING CESSATION;

EID: 41749118479     PISSN: 11782595     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03256691     Document Type: Article

References (42)

1. Kessler DA, Pines WL. The federal regulation of prescription drug advertising and promotion. JAMA 1990; 264: 2409-15
2. US Department of Health and Human Services, Food and Drug Administration, 21 CFR Part 310 section 502(a) of the Food and Drug Administration Modernization Act of 1997 (Modernization Act). 21 U.S.C. 352 (n)
3. US Food and Drug Administration. Section 502(n) of the Food Drug and Cosmetics Act, and Title 21 Code of Federal Regulations, 202.1(1)(1)
4. US Food and Drug Administration. Section 502(n) of the Food Drug and Cosmetics Act, and Title 21 Code of Federal Regulations, section 202.1 (j)(1)
5. US Department of Health and Human Services, Food and Drug Administration, 21 CFR Part 310 section 502(a) of the Food and Drug Administration Modernization Act of 1997 (Modernization Act). 21 314.81(b)(3)
6. Woodcock J (DHHS, FDA). Statement by Janet Woodcock, MSD Director, Center for Drug Evaluation and Research. US Drug Administration, Department of Health and Human Services. July 22, 2003 [online]. Available from URL: http://www.fda.gov/ola/2003/AdvertisingofPrescriptionDrugs0722.html [Accessed 2008 Feb 18]
7. Gahart MT, Duhamel LM, Dievler A, et al. Examining the FDA's oversight of direct to consumer advertising. Health Aff 2003; W3: 120-3
8. Enforcement of FDA ad regulations drops precipitously [online]. Available from URL: http://oversight.house.gov/story.asp?ID=441 [Accessed 2007 Jun 1]
9. Waxman HA. Ensuring that consumers receive appropriate information from drug ads: what is the FDA's role? Health Aff 2004; W4: 256-8
10. US Food and Drug Administration. Advertising/labeling definitions [online]. Available from URL: http://www.fda.gov/cder/handbook/adverdef.htm [Accessed 2007 Dec 1]
11. Berndt ER. Pharmaceuticals in U.S. health care: determinants of quantity and price. J Econ Perspect 2002 Fall; 16 (4): 45-66
12. Halperin RM. FDA disclosure of safety and effectiveness data: a legal and policy analysis. Duke Law J 1979 Feb; 1: 286-326
13. Tansey B. Hard sell: how marketing drives the pharmaceutical industry: a patient's right to know. How much should doctors disclose about treatments not approved by the FDA? San Fran Chronicle 2005 May 1 [online]. Available from URL: http://www.sfgate.com/cgi-bin/article.cgi?f=/c/a/2005/05/01/MNG4TCID0J1. DTL&hw=HARD+SELL+Tansey&sn=005&sc=828 [Accessed 2005 Jun 24]
14. Steinman MA, Bero LA, Chren MM, et al. Narrative review: the promotion of gabapentin: an analysis of internal industry documents. Ann Intern Med 2006; 145: 284-93
15. US Department of Justice. Warner-Lambert to pay $430 million to resolve criminal and civil health care liability relating to off-label promotion. 2004 May 13 [online]. Available from URL: http://www.usdoj.gov/opa/ pr/2004/May/04_civ_322.htm [Accessed 2007 Aug 30]
16. Oregon Attorney General files judgment with Purdue Pharma over marketing of Oxycontin [online]. Available from URL: http://www.allamericanpatriots.com/ 48722692_oregon_oregon_attorney_general_files_judgment_purdue_pharma_over_ marketing_oxycontin [Accessed 2007 Sept 6]
17. US Food and Drug Administration. Guidance for industry: consumer-directed broadcast advertisements. Washington, DC: Center for Drug Evaluation and Research, FDA, 1999 [online]. Available from URL: http://www.fda.gov/CDER/ guidance/1804fnl.htm [Accessed 2008 Feb 18]
18. US Food and Drug Administration. Guidance for industry: using FDA-approved patient labeling in consumer-directed print advertisements. Draft guidance. 2001 Apr [online]. Available from URL: http://www.bcg-usa.com/docs/ 2001/FDA200104B.pdf [Accessed 2008 Feb 18]
19. US Food and Drug Administration. FDA sees rebound in approval of innovative drugs in 2003: new innovation initiative anticipated to speed approvals in years ahead. Press release 2004 Jan 15 [online]. Available from URL: http://www.fda.gov/bbs/topics/NEWS/2004/NEW01005.html [Accessed 2008 Jan 2]
20. Abenhaim L. Lessons from the withdrawal of rofecoxib. BMJ 2004; 329: 867-8
21. A taste of new medicine. Nature Med 2006; 12: 481
22. Norman P. Generic competition 2007 to 2011: the impact of patent expiries on sales of major drugs. London: Urch Publishing, 2007
23. US Food and Drug Administration. Draft guidance for industry on good reprint practices for the distribution of medical journal articles and medical or scientific reference publications on unapproved new uses of approved drugs and ap-proved or cleared medical devices: availability [online]. Available from URL: http://www.fda.gov/ohrms/dockets/98fr/08-746.pdf [Accessed 2008 Mar 5]
24. Ziegler MG, Lew P, Singer BC. The accuracy of drug information from pharmaceutical sales representatives. JAMA 1995; 273: 1296-8
25. Dana J, Loewenstein G. A social science perspective on gifts to physicians from industry. JAMA 2003; 290: 252-5
26. Tiner R. Reasons for not seeing drug representatives. BMJ 1999; 319: 1002
27. Thomson AN, Craig BJ, Barham PM. Attitudes of general practitioners in New Zealand to pharmaceutical representatives. Br J Gen Pract 1994; 44: 220-3
28. Benbow AG. Reasons for not seeing drug representatives. BMJ 1999; 319: 1003
29. Croasdale M. Some medical schools say no to drug reps' free lunch. Stanford, Yale and the University of Pennsylvania have adopted policies to create a brighter line between medicine and marketing. Am Med News 2006 Oct 9 [online]. Available from URL: http://www.ama-assn.org/amednews/site/free/ prl21009.htm#s2 [Accessed 2007 Aug 31]
30. Brennan TA, Rothman DJ, Blank L, et al. Health industry practices that create conflicts of interest: a policy proposal for academic medical centers. JAMA 2006; 295: 429-33
31. US Food and Drug Administration, CDER. Over-the-counter drug products [online]. Available from URL: http://www.fda.gov/cder/handbook/otcintro.htm [Accessed 2008 Mar 5]
32. US Center for Drug Evaluation and Research. 2001 Report to the nation improving public health through human drugs [online]. Available from URL: http://www.fda.gov/cder/reports/rtn/2001/rtn2001.pdf [Accessed 2008 Mar 5]
33. US Department of Health and Human Services, Food and Drug Administration. Over-the-counter human drugs; labeling requirements; final rule; technical amendment. Fed Reg 2000 Jan 3; 65 (1): 7-8
34. US Food and Drug Administration. US Food and Drug Administration. Com-pliance program guidance manual. 2002 Jun 1 [online]. Available from URL: http://www.fda.gov/cder/dmpq/CPGM_7361-003_OTC1.pdf [Accessed 2008 Mar 5]
35. Caplovitz A. Turning medicine into snake oil: how pharmaceutical marketers put patients at risk. NJPIRG Law and Policy Center. 2006 May 1 [online]. Available from URL: http://www.njpirg.org/uploads/tq/WH/tqWHL32WamCJ- pj9Vxuz1g/TurningMedintoSnakeOil.pdf [Accessed 2008 Feb 18]
36. Almasi EA, Stafford RS, Kravitz RL, et al. What are the public health effects of direct-to-consumer drug advertising? PLoS Med 2006; 3: 284-8
37. Vaithianathan R. Better the devil you know than the doctor you don't: is advertising drugs to doctors more harmful than advertising to patients? J Health Serv Res Policy 2006; 11: 235-9
38. US Food and Drug Administration. Reporting unlawful sales of medical products on the internet [online]. Available from URL: http://www.fda.gov/oc/ buyon-line/buyonlineform.htm [Accessed 2007 Aug 1]
39. US Food and Drug Administration. FDA's mission statement [online]. Available from URL: http://www.fda.gov/opacom/morechoices/mission.html [Accessed 2007 Jun 10]
40. CDER, Division of Drug Marketing, Advertising, and Communications, Food and Drug Administration. Description [online]. Available from URL: http://www.fda.gov/cder/ddmac/ [Accessed 2007 May 31]
41. US Department of Health and Human Services, Food and Drug Administration, 21 CFR Part 310 Sect. 502(a) of the Food and Drug Administration Modernization Act of 1997 (Modernization Act). 21 U.S.C. 352 (a)
42. Baylor-Henry M, Drezin NA. Regulation of prescription drug promotion: direct-to consumer advertising. Clin Ther 1998; 20 Suppl. C: C86-95